Does President Trump Have the Authority to Pause and Modify the Medicare Drug Price Negotiation Program?
Event Video
Since its inception, the Inflation Reduction Act’s (IRA) Medicare Drug Price Negotiation Program has been contentiously debated. For example, several pharmaceutical manufacturers filed a lawsuit against the U.S. Department of Health and Human Services (HHS) challenging the program’s constitutionality. This webinar will discuss whether the Biden Administration’s implementation and interpretation of the IRA go beyond Congress’s intent or constitutional boundaries.
The Centers for Medicare & Medicaid Services recently issued a statement that the Trump Administration is committed to “incorporating lessons learned to date from the program and considering opportunities to bring greater transparency in the Negotiation Program. CMS intends to provide opportunities for stakeholders to provide specific ideas to improve the Negotiation Program, consistent with the goals of achieving greater value for beneficiaries and taxpayers while continuing to foster innovation.”
Accordingly, this webinar discusses whether the Trump Administration may pause the program and whether Congress should repeal the program.
Featuring:
(Moderator) John Shu, Attorney and Legal Commentator
Jeff Stier, Senior Fellow, Conumer Choice Center and Taxpayers Protection Alliance
Dan Troy, Managing Director, Berkeley Research Group
*******
As always, the Federalist Society takes no position on particular legal or public policy issues; all expressions of opinion are those of the speaker.